Zacks
Humacyte, Inc. (HUMA) Falls More Steeply Than Broader Market: What Investors Need to Know
➖
AI Sentiment
Neutral
4/10
- Home
- HUMA
HUMA
Humacyte Inc.
as of 02-13-2026 3:46pm EST
$1.01
$0.00
0.00%
Humacyte Inc is developing a disruptive biotechnology platform to deliver universally implantable bioengineered human tissues and organs designed to improve the lives of patients and transform the practice of medicine. It develops and manufactures acellular tissues to treat a wide range of diseases, injuries, and chronic conditions. Company's pipeline includes Vascular Trauma, PAD, Dailysis, Acellular Tissue Engineered Vessels, Organ Systems, Advanced Tissue Constructs.
| Founded: | 2004 | Country: | United States |
| Employees: | N/A | City: | DURHAM |
| Market Cap: | 182.6M | IPO Year: | N/A |
| Target Price: | $10.00 | AVG Volume (30 days): | 6.1M |
| Analyst Decision: | Strong Buy | Number of Analysts: | 8 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -0.26 | EPS Growth: | N/A |
| 52 Week Low/High: | $0.88 - $4.14 | Next Earning Date: | 03-27-2026 |
| Revenue: | $1,571,000 | Revenue Growth: | N/A |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | 731.05% |
| P/E Ratio: | N/A | Index: | N/A |
| Free Cash Flow: | -106403000.0 | FCF Growth: | N/A |
AI-Powered HUMA Daily Prediction
Machine learning model trained on 25+ technical indicators
Updated 2 days ago
AI Recommendation
hold
Model Accuracy: 76.25%
76.25%
Confidence
Disclaimer: This prediction is generated by an AI model and should not be considered as financial advice. Always conduct your own research and consult with financial professionals before making investment decisions.
Latest Humacyte Inc. News
HUMA Breaking Stock News: Dive into HUMA Ticker-Specific Updates for Smart Investing
Simply Wall St.
Why Humacyte (HUMA) Is Up 19.6% After New DoD Funding For Biologic Vascular Repair
📊
AI Sentiment
Positive
6/10
MT Newswires
Sector Update: Health Care Stocks Decline Monday Afternoon
📉
AI Sentiment
Negative
3/10
MT Newswires
Humacyte Says US DoD to Provide Funding for Procurement of Bioengineered Blood Vessels; Shares Rise
➖
AI Sentiment
Neutral
5/10
GlobeNewswire
Humacyte Announces New U.S. Department of Defense Funding for Procurement of Bioengineered Blood Vessels
📈
AI Sentiment
Highly Positive
9/10
Compare HUMA vs Leading Stocks
See how HUMA stacks up against similar companies in the market
Head-to-Head Comparisons
Share on Social Networks:
Tools & Resources
Enhance your trading experience with our free tools
Disclaimer
The information presented on this page, "HUMA Humacyte Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.